Cost Effectiveness of Teplizumab for Prevention of Type 1 Diabetes Among Different Target Patient Groups
Shweta Mital, Hai V. Nguyen
Topics & Concepts
Human leukocyte antigenReimbursementMedicineAlleleCost effectivenessHealth economicsImmunologyPublic healthHealth careGeneticsBiologyAntigenEconomicsRisk analysis (engineering)GeneEconomic growthNursingDiabetes and associated disordersImmunodeficiency and Autoimmune DisordersCeliac Disease Research and Management